Arcturus Therapeutics (ARCT) Earnings Date and Reports 2024

2 days ago · Arcturus Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.26, which beat the consensus estimate of -$0.70 by $0.44. Quarterly revenue was reported to be $41.67 million, below analysts' expectations of $49.16 million.

CouponFollow Extension

$0.26
OFF

Arcturus Therapeutics (ARCT) Earnings Date And Reports 2024

1 week from now

marketbeat.com

8%
OFF

Arcturus Therapeutics Holdings Earnings Dates, Reports, Calls …

1 week from now

The latest ARCT earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$17.2M, down 35.8% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ARCT …

wallstreetzen.com

$36.60
OFF

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings …

1 week from now

Nov 6, 2024 · Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $36.60 million, and …

yahoo.com

7%
OFF

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats ...

1 week from now

Nov 9, 2024 · Arcturus Therapeutics Holdings (NASDAQ:ARCT) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$41.7m (down 7.7% from 3Q 2023). Net loss: US$6.90m (loss …

yahoo.com

$1.22
OFF

Arcturus Therapeutics: Strategic Growth And Robust Pipeline …

1 week from now

6 days ago · Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones Arcturus Therapeutics reports Q3 EPS (26c), consensus ($1.22)

businessinsider.com

$1.22
OFF

Arcturus Therapeutics Receives FDA Clearance To Begin H5N1 …

1 week from now

6 days ago · Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones Arcturus Therapeutics reports Q3 EPS (26c), consensus ($1.22)

businessinsider.com

$294
OFF

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call ...

1 week from now

Nov 8, 2024 · Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has a strong financial position with cash, cash equivalents, and restricted cash totaling $294.1 million as of …

yahoo.com

$41.67
OFF

Arcturus Therapeutics (ARCT): Impressive Pipeline And ... - Nasdaq

1 week from now

5 days ago · The company recently posted results for the third quarter. Revenue of $41.67 million beat analysts’ expectations by $5.08 million.

nasdaq.com

FAQs about Arcturus Therapeutics (ARCT) Earnings Date and Reports 2024 Coupon?

When will Arcturus Therapeutics (ARCT) release its Q3 2024 earnings?

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $36.60 million, and the earnings are expected to come in at -$1.19 per share. The full year 2024's revenue is expected to be $185.54 million and the earnings are expected to be -$3.27 per share. ...

When did Arcturus Therapeutics last release its earnings results?

Arcturus Therapeutics last issued its earnings results on May 9th, 2023. The biotechnology company reported $0.88 EPS for the quarter, missing the consensus estimate of $2.92 by $2.04. The business had revenue of $80.29 million for the quarter, compared to analyst estimates of $133.50 million. ...

How did Arcturus Therapeutics Holdings Inc (ARCT) perform in one day?

Arcturus Therapeutics Holdings Inc's (NASDAQ:ARCT) actual earnings were -$0.64 per share, which beat analysts' earnings expectations of -$1.62 per share by 60.44%. After releasing the results, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) was up by 0.2% in one day. ...

What is the target price for Arcturus Therapeutics Holdings Inc (ARCT)?

After releasing the results, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) was up by 0.2% in one day. Based on the one-year price targets offered by 9 analysts, the average target price for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is $69.11 with a high estimate of $140 and a low estimate of $25. ...

Who is Arcturus Therapeutics (ARCT)?

Arcturus Therapeutics (ARCT) Company Description: Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA. ...

Does Arcturus Therapeutics have a 'study can proceed' notification?

Arcturus Therapeutics (ARCT) Holdings announced that the U.S. Food and Drug Administration has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug application, ARCT-2304, a self-amplifying mRNA vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus. ...